Full-Time
Laboratory Technician
Roche
1-10 employees
Global pharmaceuticals and diagnostics company
No salary listed
Mannheim, Germany
In Person
 Medical, Clinical & Veterinary (1) |
|---|
Get referred to Roche
See people who can refer or advise you
- You have successfully completed vocational training as a chemical laboratory technician, physics laboratory technician, or chemical-technical assistant; chemical-technical assistants must have several years of quality control experience.
- You have current or recent experience, within the last two years, in quality control, analytical methods, or end-customer diagnostic systems.
- You have experience working in a GxP environment and work independently and carefully.
- You have good knowledge of office applications such as Word and Excel and of English.
- Independently and on schedule, conduct testing of materials from external and internal manufacturing, including all preparation and follow-up work.
- Use various analytical methods, tools, and testing machines.
- Comply with applicable regulations and work instructions and document results in accordance with good manufacturing practice.
- Document and archive results in SAP, enterprise resource planning, and other electronic and paper-based systems.
- As part of batch-release preparation, check received results for plausibility and completeness.
- Identify, evaluate, and escalate quality problems and inform responsible personnel.
- Maintain and monitor control charts and promptly report unusual trends.
- Support the creation and modification of governing documents and test procedures.
- Create or modify governing documents and test procedures.
- Represent the team in project meetings and present results there.
- Plan and conduct special measurements in response to product problems and improvement measures.
- Train new colleagues and provide collegial guidance, advice, and support.
- Lead individual continuous-improvement activities using approaches such as GO Lean, agile methods, and projects.
- Organizational talent and reliability are strengths.
- Enjoyment of teamwork and willingness to approach change with curiosity are desirable.
Roche is a global leader in pharmaceuticals and diagnostics. It develops medicines and diagnostic tools that help detect, monitor, and treat diseases, using research and biotechnology to drive new therapies and tests. Roche combines drug development with in-house diagnostic products to support personalized medicine, where treatments are tailored to individual patients based on test results. Its approach differs from many peers by integrating drug discovery with diagnostic capabilities and by expanding its research through strategic acquisitions (like Genentech) to strengthen its biotechnology and R&D capabilities. The company’s goal is to improve patient outcomes and healthcare worldwide by delivering reliable medicines, accurate diagnostic tests, and data-driven care.
Company Size
1-10
Company Stage
IPO
Headquarters
Basel, Switzerland
Founded
1896
Get referred to Roche
See people who can refer or advise you
Simplify's Take
What believers are saying
- H1 2026 sales rose 6% CER, with core operating profit up 10%.
- FDA cleared cobas BV/CV and PTEN assays in July 2026, expanding diagnostics revenue.
- CHMP recommended Susvimo in July 2026, unlocking a differentiated EU eye-care launch.
What critics are saying
- Genentech sued Biocon July 30, 2026 over Perjeta biosimilar, signaling franchise erosion.
- Roche faces CHF0.6 billion 2026 loss-of-exclusivity pressure, crushing slower launches.
- Kadcyla and Ocrevus expiration timelines threaten Roche’s oncology and immunology cash engine.
What makes Roche unique
- Roche uniquely pairs blockbuster medicines with diagnostics, selling tests alongside therapies worldwide.
- AXELIOS 1 and PathAI deepen Roche’s moat in sequencing and AI pathology.
- Susvimo and cobas BV/CV show Roche turns specialty science into practical platform products.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Performance Bonus
Company News
Roche has expanded its cyclospora testing portfolio with two new research-use-only molecular PCR tests to support U.S. public health response efforts. The LightMix Modular Cyclospora assay specifically detects cyclospora, whilst the LightMix OneTube Gastro Para 2 assay detects multiple parasites including Entamoeba histolytica, Giardia, and Cyclospora cayetanensis. Both tests work with LightCycler 480 and LightCycler PRO instruments. They complement an existing assay compatible with cobas 5800, 6800, and 8800 systems. The portfolio offers flexible testing options with one, three, or six targets. Roche acquired TIB MOLBIOL in December 2021 to expand its PCR-test capabilities for emerging infectious diseases. The company's testing infrastructure includes assays for hepatitis, HIV, respiratory illnesses, and vector-borne diseases.
Roche has received FDA 510(k) clearance for its cobas BV/CV assay, a molecular diagnostic test that detects bacterial vaginosis and Candida vaginitis from a single vaginal swab sample. The PCR-based test aims to improve diagnostic accuracy compared to traditional methods like microscopy and pH testing, which have misdiagnosis rates approaching 50%. Bacterial vaginosis affects approximately 27% of women of reproductive age in North America, whilst up to 75% of women experience Candida vaginitis at least once in their lifetime. The assay uses real-time PCR technology to identify specific bacteria and yeast responsible for these conditions. The test expands Roche's sexual health testing menu on its cobas 6800/8800 systems, enabling comprehensive testing for multiple conditions from a single sample. Commercial launch is expected later this year.
Roche's Susvimo has received a positive recommendation from the European Medicines Agency's Committee for Medicinal Products for Human Use for treating neovascular age-related macular degeneration (nAMD). Susvimo is the first continuous delivery treatment that offers an alternative to standard eye injections for nAMD, requiring only two refills per year through the Contivue refillable implant. The recommendation is based on data from the LADDER, Archway and Portal studies, which showed Susvimo maintained vision equivalent to monthly intravitreal ranibizumab injections, with data supporting vision maintenance up to seven years. Approximately 95% of patients treated with Susvimo required no supplemental treatment. nAMD is a leading cause of blindness in people over 60 and affects 1.7 million in the EU. A final decision is expected from the European Commission soon.
Roche reported 6% sales growth at constant exchange rates in the first half of 2026, though this translated to a 2% decline in Swiss francs due to currency appreciation. The Swiss pharmaceutical and diagnostics company's performance was driven by strong demand for its innovative medicines and diagnostic products. The Pharmaceuticals Division grew 6% at constant exchange rates, led by Xolair, Hemlibra, Ocrevus, Phesgo, and Vabysmo. The Diagnostics Division increased 3% at constant exchange rates, driven by immunodiagnostic and clinical chemistry products. Core operating profit rose 10% at constant exchange rates. Core earnings per share grew 9% at constant exchange rates but fell 2% in Swiss francs. Key developments included multiple US priority reviews for drug candidates and positive phase III trial data. Roche also launched its Axelios 1 sequencing platform and announced an agreement to acquire PathAI. The company confirmed its 2026 outlook, expecting mid-single-digit sales growth at constant exchange rates.
Roche has appointed Dan Malarek as President and CEO of Roche Diagnostics North America. The leadership change affects a key operating segment within the Swiss healthcare company's business. Malarek previously led Foundation Medicine, a Roche affiliate focused on precision medicine and genomic insights. His background ties directly into themes shaping modern diagnostics use in healthcare. The diagnostics arm is central to how Roche supports hospitals, laboratories, and clinicians with testing platforms and data-driven tools. Areas such as test menu development, data integration with pharmaceuticals, and health system partnerships are potential focus points under the new leadership. Roche shares currently trade at CHF332.4, approximately 8% below the CHF359.2 analyst consensus target.